Table 1 Characteristics of study population
From: MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer
|  | Training cohort (N = 39) | Validation cohort (N = 39) |
|---|---|---|
Age, years – median [range] | 62 [54–70] | 66 [61–72] |
Gender - N(%) | Â | Â |
Male | 23 (59.0%) | 29 (74.4%) |
Female | 16 (41.0%) | 10 (25.6%) |
Histology of primary tumor - N(%) | Â | Â |
Adenocarcinoma | 35 (89.7%) | 39 (100%) |
Mucinous adenocarcinoma | 4 (10.3%) | - |
Chemotherapy regimen - N(%) | Â | Â |
Ox/FP regimens | 30 (76.9%) | 29 (74.3%) |
Ir/FP regimens | 7 (17.9%) | 9 (23.1%) |
FP monotherapy | 2 (5.2%) | 1 (2.6%) |
Response to chemotherapy - N(%) | Â | Â |
Objective Response (CR, PR) | 18 (46.2%) | 24 (61.5%) |
No Response (SD, PD) | 21 (53.8%) | 15 (38.5%) |
Survival, months – median [range] |  |  |
Progression-free survival | 12.2 [6.3-18.9] | 11.6 [8.6-18.3] |
Overall survival | 24.6 [15.8-37.2] | 21.5 [13.3-31.1] |